Day Two: Wednesday September 19, 2018

REGISTRATION & BREAKFAST

8:00

Introduction and Summary

8:30

Transforming Oncology with Biomarker Solutions

Zhixin Zhao

Associate Director of R&D

 

Predicine

8:45

Biomarkers & Companion Diagnostics

Transition from Clinical Biomarker to companion diagnostics. Challenges in AML Testing landscape.

Flora Berisha

Director, AML Franchise Companion Diagnostics Lead

 

Daiichi Sankyo

9:15

BiTE® in Hematologic malignancies: lessons learned from BLINCYTO and moving forward

 

Cedric Dos Santos
Principal Scientist | Clinical Biomarkers Heme/Onc TA lead

 

Amgen

9:45

Next Gen. Sequencing for Next Gen. Drugs: MRD Assessment and Drug Development.

 

Catherine Sanders

Sr. Director, Scientific Liaisons

 

Adaptive Biotechnologies

MORNING REFRESHMENTS

10:15

10:45

Measurable Residual Disease in Acute Myeloid Leukemia: Current State and Future Directions in Drug Development and Patient Management

 

Kyle MacBeth

Senior Director, Translational Development

 

Celgene

11:15

Molecular Monitoring with Signatera (RUO): Applications in MRD, treatment assessment and relapse detection

Alexey Aleshin

Medical Diretor, Oncology

Natera

11:25

High Complete Remission Rates With Oral SYK Inhibitor Entospletinib (GS-9973) in Biomarker Defined Acute Myeloid Leukemia Patients


Yang Pan

Director, Biomarker Sciences

 

Gilead Sciences

11:55

High Throughput Single-Cell DNA Analysis in AML: Resolving Clonal Heterogeneity to Move Precision Medicine Forward


Dennis Eastburn

Chief Scientific Officer

 

Mission Bio

LUNCH & NETWORKING

12:05

PANEL DISCUSSION

1:00

Current advancements and challenges in Heme Malignancy Drugs and Trial Designs - A focus on the Precision Medicine based approach.

 

Moderator: Kamala Maddali

Executive VP - Partnerships and Business Development


Cancer Genetics Inc.

Participants:

Melanie Frigault
Head of Translational Science, Acerta / AstraZeneca

 

Omar Perez
Head of Precision Medicine and Diagnostics, GSK

 

Kyle MacBeth
Senior Director, Translational Development, Celgene

 

Pietro Taverna
Exec. Dir. Translational Medicine, Sunesis

 

2:00

Vecabrutinib: a noncovalent BTK inhibitor

 

Pietro Taverna

Executive Director, Translational Medicine

 

Sunesis Pharmaceuticals

Novel Approaches

2:30

The reversible BTK inhibitor ARQ 531 demonstrates potent anti-tumor activity in ibrutinib resistant B-cell malignancies


Sudharshan Eathiraj

Senior Lead Investigator

 

Arqule

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30

Targeting ROR1 and ETS family proteins in Leukemia and Lymphoma

 

Jim Breitmeier

CEO


Oncternal

4:00

Vyxeos: Precision Drug Combination Delivery for the Treatment of Acute Myeloid Leukemia

 

Ronald Cheung

Director, Clinical Development, Hematology/Oncology

 

Jazz Pharmaceuticals

4:30

Clinical activity of duvelisib, a novel dual inhibitor of PI3K-delta and PI3K-gamma, in hematological malignancies


Michael Layon

Sr. Medical Science Liaison

 

Verastem

SUMMARY & CLOSE OF CONFERENCE

5:00

VIEW PREVIOUS DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2018 | All content produced by: Neo-Synth Ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF

Transforming Oncology with Biomarker Solutions

Zhixin Zhao

Associate Director of R&D

 

Predicine

Transition from Clinical Biomarker to companion diagnostics. Challenges in AML Testing landscape.

Flora Berisha

Director, AML Franchise Companion Diagnostics Lead

 

Daiichi Sankyo

BiTE® in Hematologic malignancies: lessons learned from BLINCYTO and moving forward

 

Cedric Dos Santos
Senior Scientist, Therapeutic Area Lead. Clinical Biomarkers

 

Amgen

Next Gen. Sequencing for Next Gen. Drugs: MRD Assessment and Drug Development.

 

Catherine Sanders

Sr. Director, Scientific Liaisons

 

Adaptive Biotechnologies

Measurable Residual Disease in Acute Myeloid Leukemia: Current State and Future Directions in Drug Development and Patient Management

 

Kyle MacBeth

Director, Translational Medicine

 

Celgene

Molecular Monitoring with Signatera (RUO): Applications in MRD, treatment assessment and relapse detection

Alexey Aleshin

Medical Diretor, Oncology

Natera

High Complete Remission Rates With Oral SYK Inhibitor Entospletinib (GS-9973) in Biomarker Defined Acute Myeloid Leukemia Patients


Yang Pan

Director, Biomarker Sciences

 

Gilead Sciences

High Throughput Single-Cell DNA Analysis in AML: Resolving Clonal Heterogeneity to Move Precision Medicine Forward

 


Dennis Eastburn

Chief Scientific Officer

 

Mission Bio

Moderator:

Current advancements and challenges in Heme Malignancy Drugs and Trial Designs - A focus on the Precision Medicine based approach.

 

Moderator: Kamala Maddali

Executive VP - Partnerships and Business Development


Cancer Genetics Inc.

Vecabrutinib: a noncovalent BTK inhibitor

 

Pietro Taverna

Executive Director, Translational Medicine

 

Sunesis Pharmaceuticals

The reversible BTK inhibitor ARQ 531 demonstrates potent anti-tumor activity in ibrutinib resistant B-cell malignancies


Sudharshan Eathiraj

Senior Lead Investigator

 

Arqule

Targeting ROR1 and ETS family proteins in Leukemia and Lymphoma

 

Jim Breitmeier

CEO


Oncternal

Vyxeos: Precision Drug Combination Delivery for the Treatment of Acute Myeloid Leukemia

Ronald Cheung

Director, Clinical Development, Hematology/Oncology

 

Jazz Pharmaceuticals

Clinical activity of duvelisib, a novel dual inhibitor of PI3K-delta and PI3K-gamma, in hematological malignancies


Michael Layon

Sr. Medical Science Liaison

 

Verastem